Aurora Investment Counsel Decreases Stock Position in Humana Inc. (NYSE:HUM)

Aurora Investment Counsel decreased its holdings in shares of Humana Inc. (NYSE:HUM) by 2.8% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 1,719 shares of the insurance provider’s stock after selling 49 shares during the period. Aurora Investment Counsel’s holdings in Humana were worth $642,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the stock. CarsonAllaria Wealth Management Ltd. grew its position in Humana by 111.4% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after purchasing an additional 39 shares during the last quarter. Hantz Financial Services Inc. purchased a new stake in shares of Humana during the second quarter valued at $35,000. Family Firm Inc. purchased a new stake in shares of Humana during the second quarter valued at $37,000. Hollencrest Capital Management acquired a new position in shares of Humana in the 2nd quarter valued at $40,000. Finally, Riverview Trust Co purchased a new position in Humana in the 2nd quarter worth $44,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Analyst Ratings Changes

HUM has been the topic of several research analyst reports. Truist Financial boosted their price target on Humana from $355.00 to $400.00 and gave the company a “hold” rating in a research note on Monday, July 15th. Morgan Stanley began coverage on Humana in a research report on Monday, June 24th. They issued an “equal weight” rating and a $374.00 target price on the stock. JPMorgan Chase & Co. raised their price target on shares of Humana from $332.00 to $396.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 21st. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Humana from $341.00 to $349.00 and gave the company a “hold” rating in a research note on Friday, August 2nd. Finally, Oppenheimer boosted their target price on shares of Humana from $370.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, August 1st. Thirteen research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $398.70.

Humana Stock Down 0.9 %

HUM stock opened at $316.60 on Tuesday. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. The firm has a 50-day moving average of $348.57 and a two-hundred day moving average of $344.23. Humana Inc. has a 12 month low of $298.61 and a 12 month high of $530.54. The company has a market cap of $38.15 billion, a price-to-earnings ratio of 19.71, a PEG ratio of 2.44 and a beta of 0.50.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, beating the consensus estimate of $5.89 by $1.07. The firm had revenue of $29.54 billion during the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The business’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter last year, the firm earned $8.94 earnings per share. As a group, analysts forecast that Humana Inc. will post 16.01 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be given a dividend of $0.885 per share. The ex-dividend date is Monday, September 30th. This represents a $3.54 annualized dividend and a dividend yield of 1.12%. Humana’s payout ratio is 22.04%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.